Figure 3
Levels of plasma borne mediators before and after probiotic supplementation. (A–J) Plasma samples of 25 sibling participants were assayed in duplicate before and after supplement by ELISA. In (A) mediators that exhibited an absolute change of more than 5% after supplement with a p-value < 0.2 are tabulated. Significant reductions in IL-12p40, IL-13, IL-15, IL-18, IL-28A, CCL2/MCP1, CCL21/C6kine, and CCL24/eotaxin 2 were observed, while TRAIL exhibited a significant increase (paired Wilcoxon rank sum test). These significantly modulated mediators are plotted in (B–J). Additional analytes were included in the panel (CRP, EGF, CCL11, FGF-2, Flt-3 ligand, fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-10, IL-12p70, IL-17A, IL-1ra, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, MCP-3, CCL22, MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, TGFα, TNF-α, TNF-β, VEGF, sCD40L, MCP-2, BCA-1, MCP-4, I-309, IL-16, TARC, CCL26, LIF, TPO, SCF, TSLP, IL-33, IL-20, IL-21, IL-23, TRAIL, CTACK, SDF-1, ENA-78, MIP-1d, TGFB-1, TGFB-2, TGFB-3) but significant differences between the pre- and post-supplement samplings were not detected (data not shown). (K) Impact of supplementation on circulating butyrate levels.
